RAP-219 Bipolar Mania Trial: Positive Result, Key Caveats

The RAP-219 bipolar mania trial met its primary endpoint, Rapport Therapeutics said on 20 October 2026: adults given the investigational drug improved by 3.1 points more than placebo on the Young Mania Rating Scale at week three, with a reported p-value of 0.045. The randomised Phase 2 study enrolled 253 adults with bipolar I disorder in an acute manic episode. These are company-reported topline results from a single three-week trial and not a regulatory approval, and the p-value is modest. This report sets out the numbers, the safety data and the limits.

RAP-219 bipolar mania trial: key takeaways

• Result: a 3.1-point placebo-adjusted improvement on the Young Mania Rating Scale at week three (p=0.045).
• Secondary measure: a 0.4-point improvement on the clinician-rated bipolar mania severity scale (p=0.024).
• Safety: no serious adverse events were reported, and every treatment-emergent event was mild or moderate.
• Watch point: agitation was reported in 16.7% on RAP-219 against 9.4% on placebo.
• Next: an FDA meeting is planned for the first quarter of 2027, and two Phase 3 trials are expected to start in the second half of 2027.

How the RAP-219 bipolar mania trial was designed

According to Rapport’s announcement of 20 October 2026, the study was randomised, double-blind and placebo-controlled, and ran in the United States. Participants had bipolar I disorder, were in an acute manic episode with a baseline Young Mania Rating Scale score of at least 25, and were treated for three weeks in an inpatient setting. Existing bipolar medicines, anxiolytics and hypnotics were stopped at screening. Patients received 0.75 mg of RAP-219 once daily after a two- or four-day titration, or placebo. Lorazepam was allowed as rescue medication at set doses, and any use was recorded as an adverse event.

Efficacy results in the RAP-219 bipolar mania trial

The Young Mania Rating Scale is an 11-item clinician-rated scale of manic symptoms. At week three, the RAP-219 group improved by a mean of 15.4 points from baseline and the placebo group by 12.3 points, a placebo-adjusted difference of 3.1 points (p=0.045). Baseline scores were 36.9 on RAP-219 and 35.8 on placebo. The company says the gap widened over time, from 0.9 points at week one to 2.2 at week two and 3.1 at week three. All 11 items improved numerically, and irritability, thought content, disruptive-aggressive behaviour and sexual interest reached nominal significance.

What the RAP-219 bipolar mania trial numbers mean

By our own arithmetic, 15.4 points off a baseline of 36.9 is about a 42% reduction on RAP-219, and 12.3 off 35.8 is about a 34% reduction on placebo. Those percentages are our calculations from the reported means and are not company figures. They show that patients on placebo also improved substantially, which is common in inpatient mania trials, and that the drug’s advantage is a few points on a 60-point scale. Whether a 3.1-point gap is clinically meaningful is a judgement the release leaves to future trials and regulators.

Safety and tolerability data from the RAP-219 bipolar mania trial

The safety data are from an interim database lock of 16 September 2026. Treatment-emergent adverse events occurred in 51.6% of patients on RAP-219 and 52.8% on placebo, and all were mild or moderate. No serious adverse events were reported. Discontinuations because of adverse events were 3.2% on RAP-219 and 0.8% on placebo. The company says orthostatic hypotension, akathisia and extrapyramidal symptoms were not reported, and that somnolence was less frequent on RAP-219 (0.8%) than on placebo (3.1%). Eight-week post-treatment safety data are still to be presented.

The agitation signal

Agitation was the most common event on RAP-219, at 16.7% against 9.4% on placebo, a gap of 7.3 percentage points by our subtraction. Insomnia was similar between arms (14.3% and 15.0%), while nausea was 5.6% against 1.6% and headache 5.6% against 10.2%. The company says agitation usually began in week one, lasted a median of two days in both groups and was judged unrelated to treatment by investigators in more than 80% of cases. Agitation is also a symptom of mania, so separating drug effect from disease is difficult in a trial like this.

Limits of the RAP-219 bipolar mania trial

• It is a single trial with topline results; the full dataset has not been published.
• The p-value of 0.045 is only just under the usual 0.05 threshold.
• Three weeks cannot show durability or relapse prevention.
• Several item-level results are described as nominal, meaning they are not adjusted for multiple comparisons.
• The study excluded other bipolar medicines, so it does not show how RAP-219 compares with current treatments.

What Rapport says happens next

Rapport plans an end-of-Phase 2 meeting with the US Food and Drug Administration in the first quarter of 2027 and expects two Phase 3 trials to start in the second half of 2027. The company is also running Phase 3 trials in focal onset seizures with the same compound. RAP-219 is described as a TARP gamma-8-selective AMPA receptor negative allosteric modulator, a mechanism not used by approved bipolar treatments. Trial registrations can be checked on ClinicalTrials.gov.

What the company and an outside expert said on the RAP-219 bipolar mania trial

Chief executive Abraham Ceesay stressed tolerability and adherence, arguing that side effects drive discontinuation. Chief medical officer Jeffrey Sevigny called the study a proof of concept. The release also quotes Gary Sachs of Massachusetts General Hospital and Harvard Medical School, who said the results show a benefit across measures without somnolence, akathisia or extrapyramidal symptoms. These are statements in a company release and should be read as such. Readers who want background on the condition can see the US National Institute of Mental Health.

Risks and caveats on the RAP-219 bipolar mania trial

• All efficacy and safety figures are company-reported topline data.
• RAP-219 is investigational and is not approved for any use.
• Phase 2 results often differ in larger Phase 3 trials.
• This is news reporting, not medical advice.

In our assessment, the RAP-219 bipolar mania trial is an encouraging but narrow proof of concept, and the real signal will come from whether a larger trial reproduces a gap of about three points with the same clean tolerability profile. See also Continuous Glucose Monitoring for Type 2 Diabetes: Promising. More in our pharmaceutical coverage.

What to watch next on the RAP-219 bipolar mania trial

• Presentation of the full data and eight-week safety follow-up at a medical meeting.
• The outcome of the FDA end-of-Phase 2 meeting.
• Design and start of the two Phase 3 trials.

Frequently asked questions

What did the RAP-219 trial show?

A 3.1-point placebo-adjusted improvement on the Young Mania Rating Scale at week three (p=0.045), as reported by the company.

Is RAP-219 approved?

No. It is an investigational drug.

When will Phase 3 start?

The company expects two Phase 3 trials to begin in the second half of 2027.

How we reported this: we relied on the company announcement of 20 October 2026 and public health pages. Our calculations are labelled. Last updated: 20 October 2026. This article is news reporting and not medical advice.